Chaluvally-Raghavan, Pradeep, PhD
Associate Professor; Linda G. and Herbert J. Buchsbaum, MD, Chair in Gynecologic Oncology
Dr. Pradeep Chaluvally-Raghavan received Ph.D. degree in 2006 from the University of Calicut, India where he focused on the role NF-kappa B activation and pro-inflammatory cytokine genes in melanoma models. After completion of graduate school, he moved to the laboratory of Dr. Yosef Yarden at the Weizmann Institute of Sciences, Israel for postdoctoral research. In Dr. Yarden’s laboratory, he studied the role of epidermal growth factor receptor (EGFR) family members in breast cancer progression.
During this period, he identified that NOTCH3 and NOTCH3-associated genes deregulate the growth of mammary epithelial cells and promote the transition of normal mammary duct to Ductal Carcinoma In Situ (DCIS) in breast cancer models. Further, during this transition phase of DCIS to invasive cancer, he characterized the role of three distinct pathways hypoxia, integrin and bone morphogenetic protein (BMP) signaling pathways.
In 2010, he joined the lab of Dr. Gordon Mills in the Department of Systems Biology at the MD Anderson Cancer Center. In Mills lab, he focused on genomic aberrations such as gene mutation or copy number variation (CNVs), and its effect on downstream signaling pathways in breast and ovarian cancer.
In 2016, he was recruited as a tenure track Assistant Professor to the Department of Obstetrics and Gynecology at the Medical College of Wisconsin. In the current position Dr. Chaluvally continues his post-doctoral work initiated in the Mills lab, and extends this research into other areas of non-coding RNA biology.
Specifically, he is studying the role of non-coding RNA in mediating transcriptional and post-transcriptional regulation of gene expression. Over the last 6 years, he has made major scientific contributions to our understanding of the role of non-coding RNA aberrations as part of the CNVs in cancer.
Research Interest
- RNA binding proteins in cancer
- RBP-induced membraneless organelles formation through phase separation
- Oncostatin signaling in cancer
- microRNA-induced transcriptional activation
- Develop RNA interference (RNAi) approaches for cancer therapy
Education / Training
- PhD in Chemoprevention and Cancer Biology – University of Calicut, Kerala, India
- Postdoctoral Research Fellow in Cancer Biology – Weizmann Institute of Sciences, Israel
- Master of Microbiology – PSG College of Arts and Science, Coimbatore, India
Mittal S, Kumar S, Gupta P, Singh M, Chaluvally-Raghavan P, Pradeep S. Protocol for the isolation of tumor cell-derived extracellular vesicles followed by in vivo metastasis assessment in a murine ovarian cancer model STAR Protocols. 21 June 2024;5(2) SCOPUS ID: 2-s2.0-85187377383 06/21/2024
Geethadevi A, Ku Z, Tsaih SW, Parashar D, Kadamberi IP, Xiong W, Deng H, George J, Kumar S, Mittal S, Zhang N, Pradeep S, An Z, Chaluvally-Raghavan P. Blocking Oncostatin M receptor abrogates STAT3 mediated integrin signaling and overcomes chemoresistance in ovarian cancer. NPJ Precis Oncol. 2024 Jun 05;8(1):127 PMID: 38839865 PMCID: PMC11153533 SCOPUS ID: 2-s2.0-85195471255 06/06/2024
Mittal S, Kumar S, Gupta P, Singh M, Chaluvally-Raghavan P, Pradeep S. Protocol for the isolation of tumor cell-derived extracellular vesicles followed by in vivo metastasis assessment in a murine ovarian cancer model. STAR Protoc. 2024 Jun 21;5(2):102943 PMID: 38470912 PMCID: PMC10945248 SCOPUS ID: 2-s2.0-85187377383 03/12/2024
Mittal S, Kadamberi IP, Chang H, Wang F, Kumar S, Tsaih SW, Walker CJ, Chaluvally-Raghavan P, Charlson J, Landesman Y, Pradeep S. Preclinical activity of selinexor in combination with eribulin in uterine leiomyosarcoma. Exp Hematol Oncol. 2023 Sep 15;12(1):78 PMID: 37715291 PMCID: PMC10503035 SCOPUS ID: 2-s2.0-85171339411 09/16/2023
AbuEid M, Keyes RF, McAllister D, Peterson F, Kadamberi IP, Sprague DJ, Chaluvally-Raghavan P, Smith BC, Dwinell MB. Fluorinated triphenylphosphonium analogs improve cell selectivity and in vivo detection of mito-metformin. iScience. 2022 Dec 22;25(12):105670 PMID: 36567718 PMCID: PMC9768319 12/27/2022
AbuEid M, Keyes RF, McAllister D, Peterson F, Kadamberi IP, Sprague DJ, Chaluvally-Raghavan P, Smith BC, Dwinell MB. Fluorinated triphenylphosphonium analogs improve cell selectivity and in vivo detection of mito-metformin Iscience. 22 December 2022;25(12) SCOPUS ID: 2-s2.0-85143723525 12/22/2022
Kumar S, Mittal S, Gupta P, Singh M, Chaluvally-Raghavan P, Pradeep S. Metabolic Reprogramming in Tumor-Associated Macrophages in the Ovarian Tumor Microenvironment. Cancers (Basel). 2022 Oct 25;14(21) PMID: 36358644 PMCID: PMC9656653 SCOPUS ID: 2-s2.0-85141848301 11/12/2022
McAlarnen LA, Gupta P, Singh R, Pradeep S, Chaluvally-Raghavan P. Extracellular vesicle contents as non-invasive biomarkers in ovarian malignancies Molecular Therapy Oncolytics. 15 September 2022;26:347-359 SCOPUS ID: 2-s2.0-85136664501 09/15/2022
McAlarnen LA, Gupta P, Singh R, Pradeep S, Chaluvally-Raghavan P. Extracellular vesicle contents as non-invasive biomarkers in ovarian malignancies. Mol Ther Oncolytics. 2022 Sep 15;26:347-359 PMID: 36090475 PMCID: PMC9420349 09/13/2022
Parashar D, Geethadevi A, Mittal S, McAlarnen LA, George J, Kadamberi IP, Gupta P, Uyar DS, Hopp EE, Drendel H, Bishop EA, Bradley WH, Bone KM, Rader JS, Pradeep S, Chaluvally-Raghavan P. Correction: Parashar et al. Patient-Derived Ovarian Cancer Spheroids Rely on PI3K-AKT Signaling Addiction for Cancer Stemness and Chemoresistance. Cancers 2022, 14, 958. Cancers (Basel). 2022 May 16;14(10) PMID: 35626175 PMCID: PMC9140135 05/29/2022
Publications of Pradeep Chaluvally-Raghavan PhD from the Faculty Collaboration Database
Recent research led by Chaluvally-Raghavan has highlighted the pivotal role of the oncostatin M receptor (OSMR) in ovarian cancer. Their findings reveal that OSMR is highly expressed in ovarian cancer...